The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
  • Login
  • Register
  • Login
  • Register
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
  • 1

    Disgraced ex-minister's daughter says she feels proud, qualified as a doctor

  • 3

    Ex-gov't employee summarily indicted for alleged attempt to sell Jungkook's lost hat

  • 5

    Coupang reveals Asia's largest fulfillment center in Daegu

  • 7

    'Celebrity forests' emerge as new K-pop trend in Seoul

  • 9

    Korean Peninsula may face fallout from balloon saga

  • 11

    SM founder Lee Soo-man returns home, in hospital to treat arm fracture

  • 13

    Rescuers race against time as Turkey-Syria quake death toll passes 5,000

  • 15

    Apple confirms launch of Apple Pay in Korea

  • 17

    INTERVIEW'Korea, US can create synergy in space industry': NASA ambassador

  • 19

    Seoul narrows in on new slogan

  • 2

    Singer Lee Seung-gi to marry actor Lee Da-in in April

  • 4

    SM in internal feud over founder's exit from producing

  • 6

    Seoul city zeroes in on foreign residents' unpaid taxes

  • 8

    Tiger endures 3 years of solitary confinement in closed zoo

  • 10

    Netflix survival show 'Physical 100' attracts viewers with sweat, muscle and human story

  • 12

    Peak Time: Survival show for lesser-known K-pop boy bands to hit air

  • 14

    Ex-justice minister, daughter blamed for unrepentant attitude over academic fraud

  • 16

    PHOTOSTurkey-Syria earthquake

  • 18

    K-pop stars and dating

  • 20

    South Korea steps up efforts to resolve issue of aging separated families

Close scrollclosebutton

Close for 24 hours

Open
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Thu, February 9, 2023 | 19:16
Business
Samsung Bioepis introduces biosimilar drug in UK
Posted : 2016-09-11 17:09
Updated : 2016-09-11 19:21
Print PreviewPrint Preview
Font Size UpFont Size Up
Font Size DownFont Size Down
  • facebook
  • twitter
  • kakaolink
  • whatsapp
  • reddit
  • mailto
  • link
By Kim Tae-gyu

Samsung Bioepis introduced SB2, a generic version of Janssen's rheumatoid arthritis treatment Remicade, in the United Kingdom last week, the biosimilar drug maker said Sunday.

After obtaining final approval in Europe in May, Boston-based powerhouse Biogen took charge of selling the medicine under the brand name Flixabi.

"The U.K. is not the first European country where SB2 commercially debuted. It also went on sales in other places in Europe," a Samsung official said. But she refused to disclose details.

Janssen's Remicade has been a blockbuster as the U.S. company had a turnover of $4.5 billion in the United States and $9.9 billion in total last year from the autoimmune disorder drug.

Earlier this year, Samsung Bioepis applied for approval from the U.S. Food and Drug Administration (FDA) to sell SB2 in the world's largest pharmaceutical market in an alliance with Merck.

Celltrion might not be happy with the news as the cross-city rival of Samsung Bioepis is also betting its future on Remsima, its own biosimilar version of Remicade.

Celltrion, the largest-capitalized corporation in Korea's tech-heavy KOSDAQ, introduced Remsima in Europe in 2013 and now has a 30 percent market share.

The firm is seeking to raise this to more than 40 percent in the near future and is poised to market the drug in the U.S. in partnership with Pfizer after getting FDA approval in April. It sent the first batch of the drugs to the U.S. last month.

Considering its potential, many global players have invested in the company. Some major investors are Singapore's sovereign wealth fund Temasek and One Equity Partners, an internal fund at JP Morgan.

Samsung Bioepis also gained regulatory approval for another biosimilar medicine called SB4 in Europe in January and commercialized it under the trade name Benepali. It copies Enbrel from U.S. pharmaceutical company Amgen, and treats rheumatoid arthritis and plaque psoriasis.

Samsung Bioepis was set up in 2012 as a joint venture between Samsung BioLogics and Biogen. The firm is responsible for developing and producing products as well as global clinical trials and regulatory registration.

Marketing, distribution and sales are carried out by Biogen and Merck, with whom Samsung Bioepis signed commercialization deals. Merck is known as MSD in Korea.

Samsung Group has shelled out big bucks on Samsung BioLogics as Korea's No. 1 conglomerate regards the bio segment as one of its main next-generation growth engines.

Emailvoc200@koreatimes.co.kr Article ListMore articles by this reporter
 
Top 10 Stories
1Korean Peninsula may face fallout from balloon saga Korean Peninsula may face fallout from balloon saga
2[PHOTOS] Turkey-Syria earthquake PHOTOSTurkey-Syria earthquake
3Daughter-centered photos, title of honor reinforce speculation over North Korea succession Daughter-centered photos, title of honor reinforce speculation over North Korea succession
4SM's management dispute to benefit KakaoSM's management dispute to benefit Kakao
5[INTERVIEW] 'Growth slowdown can accelerate depletion of retirement pension fund' INTERVIEW'Growth slowdown can accelerate depletion of retirement pension fund'
6National Assembly votes to impeach interior minister for Itaewon tragedy National Assembly votes to impeach interior minister for Itaewon tragedy
7Philip Morris seeks to surpass KT&G in e-cigarette market Philip Morris seeks to surpass KT&G in e-cigarette market
8Key real estate owned by McDonald's Korea excluded from sale Key real estate owned by McDonald's Korea excluded from sale
9SM6 Feel attracts customers with popular options, low price SM6 Feel attracts customers with popular options, low price
10Korean companies move to support victims in earthquake-hit Turkey, Syria Korean companies move to support victims in earthquake-hit Turkey, Syria
Top 5 Entertainment News
1SM in internal feud over founder's exit from producing SM in internal feud over founder's exit from producing
2Peak Time: Survival show for lesser-known K-pop boy bands to hit air Peak Time: Survival show for lesser-known K-pop boy bands to hit air
3K-pop stars and dating K-pop stars and dating
4Investigation into Yoo Ah-in's alleged drug use likely to affect release of his films, series Investigation into Yoo Ah-in's alleged drug use likely to affect release of his films, series
5Kim Ok-vin, Yoo Teo show enemies-to-lovers dynamic in 'Love to Hate You' Kim Ok-vin, Yoo Teo show enemies-to-lovers dynamic in 'Love to Hate You'
DARKROOM
  • [PHOTOS] Turkey-Syria earthquake

    [PHOTOS] Turkey-Syria earthquake

  • Nepal plane crash

    Nepal plane crash

  • Brazil capital uprising

    Brazil capital uprising

  • Happy New Year 2023

    Happy New Year 2023

  • World Cup 2022 Final - Argentina vs France

    World Cup 2022 Final - Argentina vs France

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Contact Us
  • Products & Services
  • Subscribe
  • E-paper
  • RSS Service
  • Content Sales
  • Site Map
  • Policy
  • Code of Ethics
  • Ombudsman
  • Privacy Statement
  • Terms of Service
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group